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Abstract
Background: The aim of the study was to investigate the prognostic value of selected biomarkers in 
patients with aortic regurgitation undergoing valve surgery.
Methods: A prospective study was conducted on a group of consecutive patients with hemodynamically 
significant aortic regurgitation that underwent elective aortic valve surgery. The primary endpoint was 
30-day mortality and any major adverse event within 30 days. 
Results: The study group included 205 consecutive patients who underwent replacement or repair 
of the aortic valve. The primary endpoint occurred in 72 patients. At multivariate analysis red cell 
distribution width (RDW; p = 0.03) and high-sensitivity troponin T (hs-TnT; p = 0.02) remained 
independent predictors of the major complications including death.
Conclusions: Elevated preoperative RDW and hs-TnT were associated with a poorer outcome follow-
ing aortic valve surgery. (Cardiol J 2019; 26, 5: 477–482)
Key words: aortic regurgitation, biomarkers, EuroSCORE II, risk stratification,  
high-sensitivity troponin T
Introduction
Troponin T (TnT) is a protein forming part of 
the contractile apparatus of striated muscle. More-
over TnT is a recognized biomarker of myocardial 
injury [1]. In the available literature, several stud-
ies have reported that elevated high-sensitivity 
TnT (hs-TnT) is associated with poor outcomes 
in patients with stable coronary heart disease, 
acute myocardial infarction (MI), heart failure 
(HF), dilated cardiomyopathy, atrial fibrillation or 
significant aortic stenosis [2–9]. 
Another biomarker, red cell distribution width 
(RDW), is a measure of the differentiation of the 
size of red blood cells (anisocytosis). Until now, the 
RDW parameter has been used mainly as a hema-
tological auxiliary marker indicating an increased 
destruction of erythrocytes or erythrocytes pro-
duction dysfunction related to a deficiency of folic 
acid, vitamin B12, iron or ongoing inflammation. 
Recently, numerous publications have demon-
strated the usefulness of RDW also as a prognostic 
factor for various cardiovascular diseases, such as 
coronary artery disease, chronic HF, perioperative 
stroke, idiopathic pulmonary hypertension and 
severe aortic stenosis [10–14]. The usefulness of 
hs-TnT and RDW in patients with severe sympto-
matic aortic regurgitation undergoing valve surgery 
in a 30-day follow-up are not established. As there 
is a need to complement the tools to determine the 
risk in patients with aortic regurgitation eligible for 
valve surgery it was sought to observe the useful-
ness of these biomarkers in this group of patients.
Methods
This was a prospective study of consecutive 
patients with hemodynamically significant aortic 
regurgitation (vena contracta > 6 mm, effective 
regurgitant orifice area > 30 mm2 or pressure 
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half-time < 200 ms) and without significant ath-
erosclerotic changes in the coronary arteries that 
were qualified to cardiac surgery and subsequently 
underwent elective replacement or repair of the 
aortic valve. The exclusion criteria were: a lack 
of consent to participate in the study, significant 
atherosclerotic changes in the coronary arteries 
identified by angiography, patients under 18 years 
of age, autoimmune diseases, chronic inflamma-
tory bowel, active neoplastic diseases and active 
infective endocarditis. Patients who were eligible 
for surgery but subsequently refused the proce-
dure, or did not undergo surgery for logistic or 
other reasons were not included in the study. The 
following data were collected: age, gender, body 
mass index (BMI), comorbidities (coronary artery 
disease, MI, hypertension, chronic obstructive 
pulmonary disease, stroke, diabetes), the results 
of echocardiography findings and the assessment 
of the coronary arteries. The risk of surgery using 
EuroSCORE II was calculated for each patient. The 
day before surgery a blood sample for biomarkers 
was collected from each patient. Complete blood 
count was performed with K2-EDTA samples, 
using a Cobas 6000 electronic counter (Roche, 
Mannheim, Germany). The plasma levels of cardiac 
TnT (cTnT) concentrations were measured with 
the Troponin T hs-STAT (Roche). All procedures 
were performed through a midline sternotomy inci-
sion under general anaesthesia in a normothermia. 
All patients were given cold blood cardioplegia at 
the initial dose of 15–20 mL/kg followed by booster 
doses of 5–10 mL/kg every 20 min. The primary 
end-point was death from all causes as well as: 
hemodynamic instability (defined as the need for 
a supply of catecholamines more than 48 h after 
completing the cardiopulmonary bypass surgery or 
the need to resupply), perioperative MI (defined as 
the development of new Q waves in two or more 
leads on an electrocardiogram, or alterations of 
myocardial contractility that did not previously 
exist in echocardiography), stroke (evidence of 
a new neurological deficit or a transient ischemic 
attack, confirmed by an imaging test), perioperative 
renal failure (requiring renal replacement therapy), 
prolonged mechanical ventilation (either mechani-
cal ventilatory support lasting longer than 24 h, or 
the need for reintubation) and the occurrence of 
multiple-organ failure (the dysfunction of two or 
more organs — based on laboratory parameters 
and/or the need to use organ replacement therapy). 
In all patients the follow up was conducted through 
direct observation during hospitalization, tele-
phone interviews, or clinic visits for 30 days after 
surgery. The study was conducted at the Institute 
of Cardiology, Warsaw, Poland. The protocol was 
approved by The Institutional Ethics Committee.
Statistical analysis
A statistical analysis was performed using 
SAS version 9.2. Data are presented as the mean 
± standard deviation and the frequency (%). In-
tergroup comparisons were made using the Mann-
-Whitney U test, the Pearson’s c2 test or Student 
t-test. Logistic regression was used to assess 
relationships between variables. The following 
preoperative covariates: age, atrial fibrillation, 
BMI, chronic kidney disease, chronic obstructive 
airway disease, coronary artery disease, creati-
nine, high-sensitivity C-reactive protein (hs-CRP), 
hs-TnT, hematocrit, hemoglobin, hypertension, 
left ventricular end-diastolic diameter (LVEDD), 
left ventricular end-systolic diameter (LVESD), 
left ventricular ejection fraction (LVEF), mean 
corpuscular hemoglobin, mean corpuscular hemo-
globin concentration, mean corpuscular volume, 
New York Heart Association (NYHA) classes, 
N-terminal pro-hormone of B-type natriuretic 
peptide (NT-proBNP), peripheral atherosclerosis, 
platelets, pulmonary blood pressure, red blood cell 
count, RDW, stroke history, tricuspid annulus plane 
systolic excursion and white blood cell count were 
investigated for association with the endpoints 
in univariate analysis. Significant determinants 
(p < 0.05) identified from univariate analysis were 
subsequently entered into multivariate models. 
Receiver operating characteristic (ROC) curves 
were plotted for the EuroSCORE II alone and for 
the model combined of EuroSCORE II, hs-TnT and 
RDW for 30-day survival following aortic regurgi-
tation surgery. The additional predictive value of 
RDW and hs-TnT was assessed by a comparison of 
the areas under the ROC of the respective curves.
Results
The study included 205 patients who under-
went aortic valve surgery with or without con-
comitant procedures. In 97 patients a mechanical 
aortic valve prosthesis was implanted, and in 77 
a biological valve. The mean age in the study 
group was 58.7 ± 7.7. Seven (3.4%) of the pa-
tients in the study had a previous MI, but cur-
rently none of the patients had significant ath-
erosclerotic changes in the coronary arteries. 
Sixteen (8%) patients had significantly impaired 
left ventricular systolic function (LVEF ≤ 35%). 
The mean plasma preoperative hs-TnT level was 
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20.7 ± 13.9 ng/L. Patients in NYHA class II, III 
and IV had a significantly higher levels of hs-TnT 
compared to patients in NYHA class I. Baseline 
characteristics of the patients are presented in 
Table 1.
Six patients died during the follow-up period as 
a result of gradually increasing multi-organ failure 
(2 patients with LVEF ≤ 35%, 3 patients with LVEF 
36–50%, 1 patient with LVEF > 50%). The actual 
mortality was 2.9% vs. the mortality 3.5% pre-
dicted by the EuroSCORE II model. The primary 
end-point occurred in 72 patients: perioperative 
renal failure in 11 patients, prolonged mechanical 
ventilation in 21 patients, stroke in 7 patients and 
catecholamine infusion for over 48 h in 57 patients. 
Multi-organ failure was observed in 17 patients. 
Myocardial infarction occurred in 6 patients. In 
the postoperative period, 4 patients developed 
pneumonia. In addition, 6 patients experienced 
sternal wound infections. Statistically significant 
predictors of major complications including death 
at univariate analysis are presented in Table 2. At 
multivariate analysis RDW (odds ratio [OR] 1.526; 
95% confidence interval [CI] 1.011–2.331; p = 0.03) 
and hs-TnT (OR 1.384; 95% CI 1.082–1.686; p = 0.02) 
remained independent predictors of the primary 
endpoint. A positive correlation was found be-
tween the level of hs-TnT and LVEF (r = –0.37; 
p = 0.001), moreover between RDW and CRP 
(r = 0.42; p = 0.0007). Patients with concomitant 
chronic kidney disease hadn’t significantly higher 
preoperative hs-TnT levels (p = 0.36) compared 
with patients without chronic kidney disease. The 
optimal cut-of points for primary end-point were 
calculated at the hs-TnT level of 27.5 ng/L and 
the RDW 14.2%. RDW, hs-TnT and combined with 
EuroSCORE II was a better predictor of 30-day 
major complications including death in patients 
with aortic regurgitation undergoing valve surgery 
(area under receiver operator characteristic curve 
[AUROC] = 0.802; 95% CI 0.716–0.886) compared 
with EuroSCORE II alone (AUROC = 0.699; 95% 
CI 0.601–0.797).
Figure 1 shows the areas under receiver opera-
tor characteristic curves of EuroSCORE II and the 
combined model RDW + hs-TnT + EuroSCORE II 
for 30-day major complications.
Discussion
The present paper demonstrated the prognos-
tic significance of  hs-TnT and RDW in predicting 
major complications including death in patients 
with severe symptomatic aortic regurgitation 
Table 1. Baseline characteristics of the study 
population (n = 205).
Parameters Values
Preoperative characteristics of patients
Age [years] 58.7 ± 7.7
Male: men 154 (75%)
Previous myocardial infarction 7 (3.4%)
Stroke in history 5 (2.4%)
Atrial fibrillation 62 (30%)
Peripheral atherosclerosis 4 (1.9%)
Diabetes mellitus 22 (11%)
Hypertension 115 (56%)
Current smoker 37 (18%)
Hyperlipidemia 56 (27%)
Body mass index [kg/m2] 26.8 ± 3.9
Chronic obstructive airways disease 4 (1.9%)
Chronic kidney disease  
(GFR < 60 mL/min/1.73 m2)
48 (23.4%)
LVEF > 50% 149 (73%)
LVEF 50–36% 40 (19%)
LVEF ≤ 35% 16 (8%)
LVEDD [mm] 65 ± 13
LVESD [mm] 46 ± 12
Pulmonary BP [mmHg] 39.1 ± 15.6
NYHA I class 6 (3%)
NYHA II class 112 (55%)
NYHA III class 82 (40%)
NYHA IV class 5 (2%)
EuroSCORE II [%] 3.5 ± 3.1
Hemoglobin [g/dL] 14.1 ± 1.6
RDW [%] 13.8 ± 0.4
Plateletes [1000/µL] 193 ± 51
Hs-TnT [ng/L] 20.7 ± 13.9
Hs-TnT I [ng/L] 7.3 ± 3
Hs-TnT II [ng/L] 18.4 ± 9
Hs-TnT III [ng/L] 22.2 ± 11
Hs-TnT IV [ng/L] 26.1 ± 12
NT-proBNP [pg/mL] 1922 ± 1017
GFR [mL/min/1.73 m2] 69.7 ± 17.7
Aortic regurgitation severe 205 (100%)
Aortic stenosis mild 26 (13%)
Aortic stenosis moderate 20 (10%)
Aortic stenosis severe 0 (0%)
Postoperative characteristics of patients 
Aortic cross-clamp time [min] 93 ± 36
Cardiopulmonary bypass time [min] 122 ± 53
Time at the ICU [days] 6.4 ± 4.5
Time in the hospital [days] 14.7 ± 5.7
Æ
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undergoing aortic valve surgery in postoperative 
30-day follow-up. 
Troponin T is a polypeptide that is part of the 
striated contractile muscle apparatus. The TnT 
function in all types of striated muscles is the 
same. As one of the three proteins included in the 
troponin complex, it performs key functions in the 
process of muscle contraction. A very important as-
pect, from a diagnostic point of view, is the fact that 
the sequence of troponins of cardiac origin differs 
from the sequence of skeletal muscle troponins. 
Thanks to this, after obtaining specific monoclonal 
antibodies, it became possible to use them in the 
diagnosis of ischemic heart disease. Currently, it is 
believed that cTnT is the best laboratory parameter 
in the early diagnosis of acute MI. Considering the 
fact that cytoplasm of cardiomyocytes contains 
a small amount of free troponins TnT and TnI, even 
small damage to the cell membrane (e.g. in the 
initial phase of myocardial ischemia) causes their 
release and the ability to be detected in the blood 
sample under study [15, 16]. High sensitivity 
tests, which have been available for several years, 
are able to detect very low levels of troponin T 
present in the blood with high reliability [17]. Sig-
nificant heart valve defects are often the result of 
pressure or volume overload of the heart cavities. 
Hypertrophy and remodeling of the myocardium 
is a response to increasing overload. This mecha-
nism initially restores and maintains the tension 
of the left ventricular wall. However, long-lasting 
additional burden on the myocardium causes pro-
gressive degenerative changes of the myocardium, 
which are accompanied by slow processes of ne-
crosis and fibrosis, which may be a reason for the 
presence of TnT in the blood [18–20]. 
 The predictive power of the preoperative TnT 
for death in 30-days follow-up in a group of 224 pa-
tients with surgically treated severe aortic stenosis 
was previously demonstrated [9]. Moreover, in 
a small group of 60 patients with severe aortic valve 
stenosis undergoing aortic surgery, preoperative 
TnT was an important predictor of serious post-op-
erative complications in long-term follow-up [21]. 
Also, in a study of a group of 24 patients undergoing 
mitral valve replacement surgery, elevated values 
of postoperative TnT significantly correlated with 
the length of postoperative hospital stay [22]. On 
the other hand, Piekarska et al. [23] didn’t show 
a significant correlation between postoperative 
TnT level and the results of surgical treatment 
of patients with severe aortic stenosis. It has also 
not been shown that the preoperative troponin 
improved the result of the Society of Thoracic 
Surgeons score in patients undergoing aortic valve 
replacement [24].  
Red cell distribution width is a simple, cheap 
and widely available parameter, determined in 
each patient during the standard blood test. So 
far, the predictive capacity of the RDW in the area 
of patients with valvular heart disease has been 
described in a few publications [10–14]. The pre-
dictive value of the RDW for serious complications 
and death in patients with severe aortic stenosis 
has previously been described, and the occurrence 
Table 2. Univariate analysis of predictive factors 
for the occurrence of the primary endpoint.





Age [years] 1.028 1.006–1.051 0.01
NT-proBNP [pg/mL] 1.023 1.011–1.034 0.006
Hs-TnT [ng/L] 1.095 1.033–1.134 0.004
LVEF [%] 0.959 0.935–0.983 0.001
LVEDD [mm] 1.264 1.124–1.421 0.008
Hemoglobin [g/dL] 0.663 0.543–0.811 0.006
RDW [%] 1.699 1.281–2.253 0.002
CI — confidence interval; Hs-TnT — high sensitivity troponin T; 
LVEDD — left ventricular end-diastolic diameter; LVEF — left  
ventricular ejection fraction; NT-proBNP — N-terminal pro-hormone 
of B-type natriuretic peptide; RDW — red cell distribution width
Table 1 (cont.). Baseline characteristics of the 
study population.
Parameters Values
Drainage after 12 h [mL] 552 ± 240
Drainage after 24 h [mL] 780 ± 365
Number of RBC units transfused 4.5 ± 3
RDW I 13.8 ± 0.4




AVR + supracoronary ascending  
aortic replacement
11 (5.4%)
Bentall procedure 10 (4.9%)
David procedure 3 (1.5%)
Values are represented by number (percentage) or mean ± and  
a measure of the variation of the internal standard deviation.
AVR — aortic valve replacement; AVP — aortic valve plasty; BP — 
blood pressure; GFR — glomerular filtration rate; Hs-TnT — high-
-sensitivity troponin T; Hs-TnT I, II, III, IV — high-sensitivity troponin T 
in NYHA class I, II, III, IV, respectively; ICU —  intensive care unit; 
LVEF — left ventricular ejection fraction; LVEDD — left ventricular 
end-diastolic diameter; LVESD —  left ventricular end-systolic 
diameter; NT-proBNP — N-terminal pro-hormone of B-type natriu-
retic peptide, NYHA — New York Heart Association; RDW — red 
cell distribution width (preoperative); RDW I — red cell distribution 
width measured immediately after surgery; RDW II — red cell dis-
tribution width measured one day after surgery
www.cardiologyjournal.org 481
Piotr Duchnowski et al., The usefulness of selected biomarkers in aortic regurgitation
of perioperative stroke of the central nervous 
system in the group of patients undergoing heart 
valve surgery [12, 14]. In turn, two studies on 
groups of 250 and 175 patients with severe aortic 
valve stenosis who underwent transcatheter aortic 
valve implantation showed a significant correlation 
between elevated RDW values and the occurrence 
of an increased risk of death and serious complica-
tions in long-term observation [25, 26]. So far, the 
relationship between value of RDW and worse re-
sults in numerous clinical observations hasn’t been 
fully understood and explained. In the literature the 
hypotheses available combine higher RDW values 
with the occurrence of inflammation and treat them 
as a marker of oxidative stress. This hypothesis can 
be confirmed by a significant correlation between 
the CRP value, determined by the high sensitiv-
ity method, with the RDW parameter (r = 0.42; 
p = 0.0007) as demonstrated in the presented study.
The results of the presented study indicate the 
usefulness of two laboratory parameters commonly 
used in clinical practice in  a group of patients with 
significant aortic valve regurgitation undergoing 
valve surgery. Hs-TnT, which indicates damage 
to the myocardium and RDW, which according to 
some authors indicate the physiological reserve of 
humans, may be important in making therapeutic 
decisions in patients with aortic regurgitation. It 
is worth noting that multi-organ failure which oc-
curred in 17 patients in the early post-operative 
period was the cause of all 6 deaths. 
Conclusions
It was a single-center study with a limited 
number of patients. Enlargement of the group of 
participants may allow confirmation of the results 
obtained and to develop a risk calculator using 
selected biomarkers. Further studies are needed 
regarding the suitability of other biomarkers as 
predictors of complications in patients with aortic 
regurgitation undergoing cardiac surgery. The 
results of the presented studies may be helpful in 
the perioperative risk stratification in patients with 
aortic regurgitation. It is worth noting that hs-TnT 
levels in combination with RDW and EuroSCORE II 
were better predictors of postoperative major 
complications including death compared to Euro-
SCORE II alone. 
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